Drug Trial Radar · NCT01908829
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,174
Actual
Start
Jul 10, 2013
Primary completion
Nov 24, 2014
Study completion Nov 25, 2014
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
Conditions
- Urinary Bladder Diseases
- Urinary Bladder Overactive
- Urologic Diseases
Interventions
mirabegron 25 mgDrug
Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
mirabegron 50 mgDrug
Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
solifenacin 5 mgDrug
Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
solifenacin 10 mgDrug
Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
mirabegron 25 mg matching placeboDrug
Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
mirabegron 50 mg matching placeboDrug
Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
solifenacin 5 mg matching placeboDrug
Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
solifenacin 10 mg matching placeboDrug
Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and end of treatment (up to 12 weeks)
Locations
219 sites in 31 countries. Site status is shown where the registry gives one.
Genova Clinical Research
Tucson, Arizona
Associated Pharmaceutical Research Center, Inc.
Buena Park, California
The American Institute of Research
Los Angeles, California
Bayview Research Group
Valley Village, California
Meridien Research
Brooksville, Florida
Innovative Research of West FL
Clearwater, Florida
Best Quality Research Inc.
Hialeah, Florida
Palmetto Professional Research
Hialeah, Florida
Urology Center of Central Florida
Kissimmee, Florida
Meridien Research
Tampa, Florida
Stedman Clinical Trials
Tampa, Florida
Private Practice
West Palm Beach, Florida
Meridian Clinical Research, LLC
Savannah, Georgia
Herman Clinical Research
Suwanee, Georgia
North Idaho Urology
Coeur d'Alene, Idaho
First Urology, PSC
Jeffersonville, Indiana
Deaconess Gateway Health Center
Newburgh, Indiana
MedStar Health Research Institute
Hyattsville, Maryland
Bay State Clinical Trials, Inc.
Watertown, Massachusetts
Beyer Research
Kalamazoo, Michigan
Quality Clinical Research
Omaha, Nebraska
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico
Brooklyn Urology Research Group
Brooklyn, New York
Advanced Urology Centers of New York
Garden City, New York
Premier Medical Group of the Hudson Valley PC
Kingston, New York
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York
PMG Research of Raleigh, dba PMG Research of Cary
Cary, North Carolina
Alliance Urology Specialists
Greensboro, North Carolina
Wake Research Associates LLC
Raleigh, North Carolina
PMG Research of Winston-Salem, LLC
Winston-Salem, North Carolina
The Urology Group
Cincinnati, Ohio
Providence Health Partners
Dayton, Ohio
The Clinical Trial Center
Jenkintown, Pennsylvania
Health Concepts
Rapid City, South Dakota
Jean Brown Research
Salt Lake City, Utah
Alexandria Clinical Research
Alexandria, Virginia
Site: 37402
Yerevan, Armenia
Site: 37403
Yerevan, Armenia
Site: 37405
Yerevan, Armenia
Site: 61006
Adelaide, Australia
Showing 40 of 219 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.